Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Small Cell Lung Carcinoma 11Lung Neoplasms 5Breast Neoplasms 2Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Advanced Solid Tumors 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × amrubicin × Clear all
NCT01033032 2022-05-03

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

SCRI Development Innovations, LLC

Phase 1/2 Completed
78 enrolled 15 charts
Breast

Breast Neoplasms

NCT00380835 2008-09-23

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Celgene

Phase 2 Withdrawn
66 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡